Skip to main content
. 2020 Jun 30;11(26):2531–2542. doi: 10.18632/oncotarget.27640

Figure 3. In vitro cell viability and signal transduction pathway analysis of sorafenib (SOR)-resistant cell line with lenvatinib treatment by a comprehensive protein phosphorylation array.

Figure 3

(A) The sensitivities of PLC/PRF5 and PLC/ PRF5-R2 to lenvatinib (LEN) were assessed by MTT assays. (B) A list of LEN-related signal transduction pathways significantly altered after treatment with LEN in PLC/PRF5 and PLC/PRF5-R2 cells. The 114 LEN related pathways were categorized into “Signaling by FGFR”, “Signaling by PDGF”, “Signaling by VEGFR”, and “Signaling by SRC-KIT” among 377 pathways tested. (C) Boxplot analysis of degree of phosphorylation of associated proteins belonging to the 63 FRS2-related transduction pathways in PLC/PRF5 and PLC/ PRF5-R2 cells in response to LEN. The boxes show the interquartile rage with the median value indicated by the horizontal line; whiskers show the range and circles indicate outliers. * p < 0.0014.